Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
about
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis CSystematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-AnalysisHCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsOral antiviral therapies for chronic hepatitis C infectionEmerging therapies for the treatment of hepatitis CDaclatasvir: potential role in hepatitis CEmerging therapeutic options for the management of hepatitis C infectionDaclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysisDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisHepatitis C.A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivityRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionNS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.Hepatitis C treatment: where are we now?Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.CUFA algorithm: assessment of liver fibrosis using routine laboratory data.Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis CHepatitis C virus NS5A inhibitors and drug resistance mutations.Direct-acting antivirals for chronic hepatitis C.Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C.Predictive factors associated with hepatitis C antiviral therapy response.High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.Treatment decisions and contemporary versus pending treatments for hepatitis C.Emerging treatments for hepatitis C.Novel therapeutic approaches for hepatitis C.Treatment of hepatitis C virus genotype 3-infection.Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.Novel drugs in the management of difficult-to-treat hepatitis C genotypes.Daclatasvir for the treatment of hepatitis C virus infection.Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.New treatments for chronic hepatitis C: an overview for paediatricians.
P2860
Q26745769-9B2F9560-1656-4BDF-9B3C-1E9FE92A9A38Q26768128-311E1DEB-7244-4183-95E4-5AE5A72E315FQ26771458-97B744A8-2752-4965-B09F-4F152B9E224AQ26782405-1F592CC5-3967-4B3B-B865-1DEF3C7FDD39Q26798477-39A5E083-758D-406C-954F-4C2EA6A370D3Q26830426-1E92D26C-FA26-41F6-8B77-24AB8059E035Q27003319-E757456B-74A2-4ADE-96F9-26F2BF03D995Q27012741-55B1F4C0-6DA9-40BE-AD67-B3D723E341D1Q27012744-1D8EF6AB-A979-4E44-AE25-ADF42D1D7711Q28073108-AED0D73E-8286-416B-97DD-42C9EB2FC9E5Q28077287-625CABC6-4998-47B3-B573-A4F298CE3953Q28084654-56F6BFFD-5506-416C-8F9A-9C3E92761378Q28537708-D83447F1-3682-4D2B-B3E8-08D1D2B673A3Q28545971-96072B4E-B05F-4A08-9FBF-EC839D5BD02AQ30352718-8D14CA45-2BD9-43E0-B8A2-E7B1D5804F3DQ30378509-01E4AB64-A401-449B-97E9-09687E603B0EQ30685690-0C81181E-4F42-4153-B7E4-158DDA4DA12CQ30834803-E48778EA-E1E1-464C-80DB-FC8A18CE3EDBQ33622970-EB7456F1-7061-46EC-B6AD-3EB7FFD6ACAFQ34113840-1DC11154-3DD2-4143-AAA8-3AC88AF65DE0Q34160592-5D61901D-FEDE-462A-8824-6347B4861D45Q34411617-10CA54D0-2CD3-494C-AE85-715E23D5DF0BQ34557595-99596DB6-3958-43A6-AEFD-1636EE844DB2Q34725990-26C43B90-99AC-48C5-8EEC-B1985EDA951FQ35790397-139243C4-4E38-4404-A1AD-65CB18BA27A0Q35907984-AAC668F5-4761-43A1-80A1-25AA9D391EABQ36668891-C5D1A54A-4DBA-47FF-9F34-5E1A8B3C480DQ36785846-AC7015C2-8225-4EC5-A756-77B5C4510D16Q37263769-233F3BA5-5B53-4485-BEDD-580AC344A9B4Q37263870-AB349DCF-AD1A-4D14-8309-B93A2822EE53Q37699395-97F30EEA-8689-4653-AE9A-CD1D15ACAD21Q38135774-FA8B99B3-2220-4542-B56F-D480AE8B0E19Q38150403-08B67884-733C-4B9C-9632-AD6F3A81A133Q38152674-2FDB999E-B6D4-4D4A-BF9A-66DEFF954816Q38174244-BD53E856-BAF6-4139-8698-D9DD2F1934DBQ38174251-2D7831BC-DB55-4662-B9EA-4AE70DBF82EDQ38201712-B29E1BDD-F90E-4BC5-B54E-1079174BA036Q38216586-40E0ED91-D190-4466-8A38-E6181B958245Q38265395-C74067AB-C57E-4820-83B3-BC216DF25941Q38282842-B8B2A08F-6884-4D2B-BE3C-42D84851ABBE
P2860
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@en
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@nl
type
label
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@en
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@nl
prefLabel
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@en
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@nl
P2093
P50
P1476
Daclatasvir for previously unt ...... dose-finding, phase 2a trial.
@en
P2093
Christophe Hézode
Claudia Martorell
David W Morris
Dennis Hernandez
Eric A Hughes
Fiona McPhee
Gary A Abrams
Greg T Everson
Harvey A Tatum
Jean-Pierre Bronowicki
P304
P356
10.1016/S1473-3099(12)70138-X
P577
2012-06-18T00:00:00Z